IBRX INVESTOR ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc.GlobeNewsWire • 04/16/26
Robbins LLP Urges IBRX Stockholders Who Lost Money Investing in ImmunityBio, Inc. to Contact the Firm for Information About Leading the Class ActionPRNewsWire • 04/16/26
REMINDER: ImmunityBio, Inc. Investors With Significant Losses Must Act By May 26, 2026GlobeNewsWire • 04/16/26
INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action - Hagens BermanPRNewsWire • 04/15/26
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRXNewsfile Corp • 04/15/26
ImmunityBio, Inc. (IBRX) Securities Fraud: Contact Berger Montague To Discuss Your RightsNewsfile Corp • 04/15/26
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Violated FDA Drug Rules: Levi & KorsinskyPRNewsWire • 04/15/26
CLASS ACTION NOTICE: Berger Montague Advises ImmunityBio, Inc. (NASDAQ: IBRX) Investors to Inquire About a Securities Fraud Class ActionPRNewsWire • 04/14/26
Faruqi & Faruqi, LLP Highlights Class Action Against ImmunityBio (IBRX) and Upcoming Lead Plaintiff Deadline of May 26, 2026Newsfile Corp • 04/13/26
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – IBRXGlobeNewsWire • 04/13/26
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewsWire • 04/13/26
Lowey Dannenberg Notifies ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmGlobeNewsWire • 04/13/26
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRXNewsfile Corp • 04/12/26
IBRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action LawsuitBusiness Wire • 04/10/26
Berger Montague PC Investigating Claims on Behalf of ImmunityBio, Inc. (IBRX) Investors After Class Action FilingNewsfile Corp • 04/10/26
ROSEN, A LONGSTANDING FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRXNewsfile Corp • 04/09/26
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable SecuritiesBusiness Wire • 04/09/26
IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff RoleBusiness Wire • 04/08/26
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action LawsuitPRNewsWire • 04/08/26
ImmunityBio, Inc. Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLPGlobeNewsWire • 04/07/26
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law FirmPRNewsWire • 04/07/26
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the FirmPRNewsWire • 04/07/26